Rojas RI, Vigoa AL, García VY, Bello RI, Duncan RY

Language: Spanish
References: 25
Page: 1-17
PDF size: 437.16 Kb.

ABSTRACT

Objective: Evaluate the safety of HeberFERON in the treatment of basal cell eyelid carcinoma. Methods: A descriptive study was conducted of patients with basal cell eyelid carcinoma undergoing perilesional HeberFERON therapy from January 2013 to January 2018. The sample was composed of 20 patients meeting the inclusion criteria. The protocol dose was 3.5 x 106 UI perilesional twice a week for five consecutive weeks. The variables analyzed were age, sex, skin color and tumor location, as well as adverse event type and degree. Absolute and relative frequencies were estimated for all the study variables. Results: The prevailing age group in the study basal cell eyelid carcinoma population was 60-79 years (80%). The most common lesion site was the lower eyelid (60%). Eyelid erythema and injection site pain were the most frequent ocular adverse events (95.0% and 70.0%, respectively), presenting in 95% of the study subjects. Systemic adverse events (fever, arthralgia and headache) prevailed in 100% of the cases studied, among whom the degree of severity was mild. Conclusions: HeberFERON is a good non-surgical alternative for basal cell eyelid carcinoma. It is safe and well tolerated.

REFERENCES

1. Rojas Rondón I, Agramonte Centelles IC, Río Torres M. Afecciones palpebrales. La Habana: Editorial Ciencias Médicas; 2018.

2. Rojas Rondón I, Mendoza Pérez M, Rodríguez Masó S. Concordancia entre el diagnóstico clínico y el anatomopatológico de los tumores malignos del párpado. Rev Cubana Oftalmol. 2019;27(1):79-90.

3. Ministerio de Salud Pública. Anuario estadístico de Salud 2018. La Habana: Dirección de Registros Médicos y Estadística de Salud; 2019.

4. Telich JE, Monter A, Baldín A, Apellaniz A. Diagnóstico y tratamiento de los tumores malignos de piel. Acta Med Grupo Ang. 2017;15(2):154-60.

5. Wu Peggy A, Stern Robert S, Robinson June K, Corona R. Epidemiology, pathogenesis, and clinical features of basal cell carcinoma. Up To Date; 2019 [acceso: 08/01/2021]. Disponible en: https://www.uptodate.com/contents/epidemiology--and-clinical-features-of-basal-cell-carcinoma

6. Jonasch E, Frank G. Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. The Oncol. 2001;6:34-55.

7. Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, et al. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1 coinfected subjects. Clin Infect Dis. 2007;44(10):1375-83.

8. Vial T, Descotes J. Clinical toxicity of the interferons. Drug safety. 1994;10:115-50.

9. Wang YX, Xu WG, Sun XJ, Chen YZ, Liu XY, Tang H, Jiang CL. Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2. J Neuroimmunol. 2004;156(1-2):107-12.

10. Vilcek J, Gray PW, Rinderknecht E, Sevastopoulos CG: Interferon gamma: a lymphokine for all seasons. In: Pick E, editor. Lymphokines. Academic Press; 1984:1-32.

11. Duff GW, Durum SK. The pyrogenic and mitogenic actions of interleukin-1 are related. Nature. 1983;304(5925):449-51.

12. EE.UU. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) versión 4.02. DHHS; 2009 [acceso: 08/01/2021]. Disponible en: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf

13. Bello Rivero I, García Vega Y, Valenzuela Silva C, Bello Álvarez C, Vázquez Blomquist D, López Saura P. Development of a new formulation of interferons. (HEBERPAG) for BCC treatment. J Cancer Res Ther. 2013;1(10):235-43.

14. Anasagasti Angulo L, García Vega Y, Pérez S, Lòpez Saura P, Bello Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open prospective study. BMC Cancer. 2009;9:262. DOI: https://doi.org/10.1186/1471-2407-9-262

15. Anasagasti Angulo L, García Vega Y, Collazo S, Jiménez Barban Y, Tijerino Arrieta E, Ballester Caballero Y. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. AMJ. 2017;10(6):509-15.

16. Kale SM, Patil SB, Khare N, Math M, Jain A, Jaiswal S. Clinicopathological analysis of eyelid malignancies. A review of 85 cases. Indian J Plast Surg. 2012;45(1):22-8.

17. Pfeiffer MJ, Pfeiffer N, Valor C. Descriptive study on basal cell eyelid carcinoma. Arch Soc Esp Oftalmol. 2015;90(9):426-31.

18. Mak ST, Wong AC, Io I, Tse R. Malignant eyelid tumors in Hong Kong 1997-2009. Jpn J Ophthalmol. 2011;55(6):681-5.

19. Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM. Squamous cell carcinoma of the eyelids. Br J Ophthalmol. 2002;86(10):1161-5.

20. Negrín Cáceres Y, Cabrera Romero AC, Cárdenas Monzón L, Ferrer Perez A, Batista Hernàndez NE. Synergestic effect of combined IFN- Alpha-2b and Gamma treatment for pericular Basal Cell Carcinoma. Rev Mex Oftalmol. 2018;92(3):136-43.

21. Fernández Martori M, Bello Rivero I, Duncan Roberts Y. Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care Med Rev. 2018;20(1):11-7.

22. Chang AL, Lewis KD, Arron ST, Migden MR, James A, Solomon JA, et al. Safety and efficacy of vismodegib in patients aged = 65 years with advanced basal cell carcinoma. Oncotarget. 2016;7(46):76118-24.

23. Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016;8(5):375-82.

24. Bernia E, Llombart B, Serna Guillén C, Bancalori B, Nagore E, Requena C, et al. Experiencia con vismodegib en carcinoma basocelular avanzado en centro oncológico. Actas Dermosifiliogr. 2018;109(9):813-20.

25. Ciudad Blanco C. Eficacia de vismodegib en pacientes con carcinoma de células basales de alto riesgo. Brit J Dermatol. 2014;171(1):1066-72.